Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs
Xconomy
APRIL 16, 2019
Drug discovery startup Insitro burst onto the scene last year with ambitions of using machine learning techniques to find new therapies. Insitro announced Tuesday that Gilead (NASDAQ: GILD ) will pay the South San Francisco-based startup $15 million to kick off a three-year research collaboration.
Let's personalize your content